Acute degron-mediated RUNX1 loss reprograms enhancer activity to epigenetically drive epithelial destabilization and initiate cancer hallmarks
Fritz, A.; Greenyer, H.; Dillac, L.; Chavarkar, P.; Ullah, R.; Malik, M.; Hong, D.; Toor, R.; Pacht, E.; Person, A.; Zotkin, G.; Korzec, S.; Gao, C.; Abuarqoub, A.; Warren, J.; Del Porto, J.; Perelman, J.; Montecino, M.; Lian, J.; Van Wijnen, A.; Heath, J.; Ghule, P.; Frietze, S.; Stengal, K.; Reed, K. S. M.; Misteli, T.; Gordon, J.; Stein, J.; Stein, G.
Show abstract
The RUNX1 transcription factor mediates cell-type specific gene expression. RUNX1 suppression and perturbations are recurrently associated with breast tumor initiation and progression. However, the mechanisms governing the dual roles of RUNX1 in sustaining the mammary epithelial phenotype while epigenetically suppressing initiation of cancer-compromised gene expression are poorly understood. To address this, we used the power of degron-mediated acute, selective, and complete RUNX1 ablation in human mammary epithelial cells. RUNX1 mediates promoter and distal enhancer-driven expression of a gene cohort. Dynamic epigenomic responsiveness upon RUNX1 ablation reveals a rapid and selective decrease in chromatin accessibility and H3K27ac at RUNX1-bound enhancers, but not promoters. While differentially initiated and expressed genes contacted by RUNX1-bound enhancers are enriched in pathways involved in epithelial maintenance and stemness, genes with RUNX1-promoter occupancy support DNA damage responsiveness. Modified cell morphology, metabolic control, increased breast cancer stemness, plasticity, anchorage-independent survival, chemoresistance, and perturbed DNA damage reactivity are observed upon RUNX1 ablation. Together, these findings define RUNX1 as an epigenetic tumor suppressor that maintains epithelial cell state by preserving enhancer activity and preventing gene expression associated with hallmarks of cancer.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.